Adhera Therapeutics Inc. · OTC:ATRX
Adhera Therapeutics — Marina Biotech — 2015 BIO International Convention
14 slides from Adhera Therapeutics's conference presentation, Jun 17, 2015
Slide 1: Nucleic Acid Therapeutics and Rare Diseases
Nucleic Acid Therapeutics and Rare Diseases 2015 BIO International Convention 16 June 2015
Slide 2: Forward Looking Statement
Forward Looking Statement This document contains forward-looking statements about Marina Biotech, Inc. (the “Company”) that are based on current management expectations. These statements reflect the Company’s current views with respect to uncertain future events and are based on imprecise estimates
Slide 3: Marina Biotech – A Leading RNA Therapeutics Company
Marina Biotech – A Leading RNA Therapeutics Company Marina has the capability to develop and deliver novel single- and double-stranded oligonucleotides . . . Marina siRNA Antisense microRNA mimics & antagomirs . . . with a clinical pipeline focused in rare diseases.
Slide 4: Marina has the Chemistries to Develop Single- AND Double-Stranded Oligonucleotides
Marina has the Chemistries to Develop Single- AND Double-Stranded Oligonucleotides Unlocked nucleobase monomers (UNM) – Allows development of double-stranded oligonucleotides that engage the RNAi pathway Conformationally restricted nucleotides (CRN) – Allows development of stable, high affinity, sin
Slide 5: Marina’s Delivery Capability is Unparalleled Within the Sector
Marina’s Delivery Capability is Unparalleled Within the Sector Systemic Delivery SMARTICLES Relapsed/Refractory non-Hodgkin’s Lymphoma1 Hepatocellular Carcinoma2 Targeted Delivery TrpCage-based Peptides Prostate Cancer Oral Delivery tkRNAi Familial Adenomatous Polyposis3 Local Delivery DiLA2 Bladder
Slide 6: Most Versatile Delivery System in Clinical Development – SMARTICLES
Most Versatile Delivery System in Clinical Development – SMARTICLES® Effective delivery of single-stranded and double-stranded nucleic acids ProNAi Therapeutics - PNT2258 (24mer single-stranded DNA decoy) Mirna Therapeutics - MRX34 (19-21mer double-stranded microRNA mimic) Delivery to cell nucleus (
Slide 7: Only Orally Available RNAi Delivery Technology in Clinical Development - tkRNAi
Only Orally Available RNAi Delivery Technology in Clinical Development - tkRNAi ™ Non-pathogenic bacteria engineered to produce, deliver and release interfering RNA mediators (shRNA) to targeted tissue Efficient delivery to the epithelium of the gastrointestinal tract via oral administration Safe an
Slide 8: Broad, Young and Issuing Intellectual Property Estate
Broad, Young and Issuing Intellectual Property Estate Technology US Issued or Allowed Foreign Issued or Allowed Worldwide Pending Biochemistry Unlocked Nucleobase Monomers (UNM) 2 6 25 Conformationally Restricted Nucleotides (CRN) 3 -- 12 Delivery Liposome Systems 14 82 44 Liposome Manufacturing Met
Slide 9: Partner of Choice for Rare Disease Therapeutic R&D
Partner of Choice for Rare Disease Therapeutic R&D
Slide 10: Three Nucleic Acid-based Strategies for Therapeutic Intervention in DM1
Three Nucleic Acid-based Strategies for Therapeutic Intervention in DM1 Accumulation of altered DMPK mRNA in nucleus sequesters Muscleblind (MBNL1) protein resulting in loss-of-function 1. Steric Blocking Displace/disrupt the MNBL-CUGn+x interaction 2. mRNA Translational Inhibition RNAi or Rnase H-d
Slide 11: Marina’s Unique Ability to Move Multiple Compounds into Preclinical Development
Marina’s Unique Ability to Move Multiple Compounds into Preclinical Development for a Single Indication RNAi-dependent Translational Blocker RNase H-dependent Translational Blocker Targeting DMPK mRNA to increase degradation and elimination Steric Blocker RNase H-dependent Translational Blocker Targ
Slide 12: Partnering Opportunity
Partnering Opportunity NOP
Slide 13: Marina’s Near Term Partnering Focus
Marina’s Near Term Partnering Focus Rare Diseases Collaboration/licensing of current pipeline Out-licensing of CEQ508 in Europe, Asia and ROW territories Preclinical collaboration in Duchenne muscular dystrophy Fast-follower approach with IND potential within 24 months: Amyotrophic lateral sclerosis
Slide 14: Thank You
Thank You ¥